FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies and their antigen-binding fragments, which bind to claudin 6 (CLDN6), as well as conjugates of these antibodies for CLDN6 detection. Hybridomas producing said antibodies are also provided. Anti-CLDN6 antibodies are used to diagnose cancer and to determine expression of CLDN6 cancer cells.
EFFECT: invention provides binding to CLDN6 in FFPE tissues affected by cancer, with high specificity and low background activity.
28 cl, 6 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
